title: Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma.
abstract: OBJECTIVE
  Laryngeal carcinomas always resist to radiotherapy. Hypoxia is an important factor in radioresistance of laryngeal carcinoma. Glucose transporter-1 (GLUT-1) is considered to be a possible intrinsic marker of hypoxia in malignant tumors. We speculated that the inhibition of GLUT-1 expression might improve the radiosensitivity of laryngeal carcinoma.
  
  
  METHODS
  We assessed the effect of GLUT-1 expression on radioresistance of laryngeal carcinoma and the effect of GLUT-1 expressions by antisense oligodeoxynucleotides (AS-ODNs) on the radiosensitivity of laryngeal carcinoma in vitro and in vivo.
  
  
  RESULTS
  After transfection of GLUT-1 AS-ODNs: MTS assay showed the survival rates of radiation groups were reduced with the prolongation of culture time (p<0.05); Cell survival rates were significantly reduced along with the increasing of radiation dose (p<0.05). There was significant difference in the expression of GLUT-1mRNA and protein in the same X-ray dose between before and after X-ray radiation (p<0.05). In vivo, the expressions of GLUT-1 mRNA and protein after 8Gy radiation plus transfection of GLUT-1 AS-ODNs were significant decreased compared to 8Gy radiation alone (p<0.001).
  
  
  CONCLUSIONS
  Radioresistance of laryngeal carcinoma may be associated with increased expression of GLUT-1 mRNA and protein. GLUT-1 AS-ODNs may enhance the radiosensitivity of laryngeal carcinoma mainly by inhibiting the expression of GLUT-1.
authors: Department of Radiotherapy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
authors: Sen-Xiang
authors: SX
authors: Yan
authors: Xing-Mei
authors: XM
authors: Luo
authors: Shui-Hong
authors: SH
authors: Zhou
authors: Yang-Yang
authors: YY
authors: Bao
authors: Jun
authors: J
authors: Fan
authors: Zhong-Jie
authors: ZJ
authors: Lu
authors: Xin-Biao
authors: XB
authors: Liao
authors: Ya-Ping
authors: YP
authors: Huang
authors: Ting-Ting
authors: TT
authors: Wu
authors: Qin-Ying
authors: QY
authors: Wang
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects / Q000528:radiation effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D016373:DNA, Antisense / Q000235:genetics / Q000502:physiology; D005434:Flow Cytometry; D051272:Glucose Transporter Type 1 / Q000235:genetics*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000532:radiotherapy* / Q000628:therapy*; D051379:Mice; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D016373:DNA, Antisense; D051272:Glucose Transporter Type 1
keywords: Glucose transporter-1; Laryngeal carcinoma; Radiosensitivity; antisense oligodeoxynucleotides
references: Hepatobiliary Pancreat Dis Int. 2011 Feb;10(1):72-7
references: 21269938
references: Oral Oncol. 2007 Sep;43(8):796-803
references: 17207657
references: Head Neck. 2009 Dec;31(12):1624-33
references: 19441091
references: Nucl Med Commun. 2010 Jun;31(6):532-8
references: 20220543
references: Chin Med J (Engl). 2013 Jan;126(1):88-94
references: 23286484
references: Head Neck. 2012 Oct;34(10):1395-402
references: 22052623
references: Pathol Oncol Res. 2012 Jul;18(3):721-8
references: 22270867
references: Lancet Oncol. 2008 Mar;9(3):288-96
references: 18308254
references: J Nucl Med. 2010 Apr;51(4):632-8
references: 20351353
references: Asian Pac J Cancer Prev. 2012;13(4):1289-95
references: 22799321
references: Oncol Rep. 2010 Apr;23(4):1069-76
references: 20204293
references: Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):61-71
references: 23081821
references: Cancer Lett. 2012 Mar;316(1):53-61
references: 22108532
references: J Int Med Res. 2010;38(6):1885-92
references: 21226991
references: Eur J Gynaecol Oncol. 2007;28(5):386-8
references: 17966218
references: Cancer Lett. 2000 Jun 30;154(2):175-82
references: 10806305
references: BMC Cancer. 2011 May 12;11:167
references: 21569415
references: ORL J Otorhinolaryngol Relat Spec. 2008;70(3):189-94
references: 18401196
references: Oncol Rep. 2008 Jan;19(1):111-6
references: 18097583
references: Oncol Lett. 2013 Jan;5(1):261-266
references: 23255932
references: Bioconjug Chem. 2002 May-Jun;13(3):525-9
references: 12009942
references: Yonsei Med J. 1995 Dec;36(6):480-6
references: 8599249
references: Surgery. 2005 May;137(5):536-44
references: 15855926
references: Semin Cell Dev Biol. 2012 Jun;23(4):352-61
references: 22406683
references: Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93
references: 17520257
references: Cancer Lett. 2011 Dec 26;313(1):64-75
references: 21945852
references: Life Sci. 1999;65(1):63-70
references: 10403494
references: CA Cancer J Clin. 2013 Jan;63(1):11-30
references: 23335087
references: Cancer Biother Radiopharm. 2008 Dec;23(6):701-14
references: 19317609
references: Arch Med Res. 2012 Jul;43(5):395-401
references: 22835601
references: Arch Biochem Biophys. 2000 Jan 1;373(1):72-82
references: 10620325
references: Cancer Res. 2011 Mar 1;71(5):1647-57
references: 21239473